STM2457

STM2457 is a first-in-class, highly potent, bioavailable, and selective small molecule inhibitor of the methyltransferase METTL3 (methyltransferase-like 3). METTL3 catalyzes the methylation of adenosine at the N6 position (m6A) in RNA, a major post-transcriptional modification regulating gene expression. STM2457 binds competitively at the S-adenosyl methionine (SAM) binding site of METTL3, inhibiting its methyltransferase activity. This leads to decreased m6A methylation in RNA, suppressing proliferation, promoting differentiation, and inducing apoptosis in cancer cells, particularly acute myeloid leukemia (AML). STM2457 has demonstrated anti-leukemic activity in preclinical AML models and is also under preclinical investigation for indications including non-small cell lung cancer, pancreatic cancer, ototoxicity prevention, and spinal cord injury. STM2457 is still in preclinical development and has not been approved for clinical use[1][3][4][5][9][10].